S&P Futures
3,902.00 +4.25 (+0.11%) Dow Futures
31,241.00 +39.00 (+0.12%) Nasdaq Futures
11,838.00 -40.25 (-0.34%) Russell 2000 Futures
1,771.50 -3.40 (-0.19%) Crude Oil
110.35 +0.46 (+0.42%) Gold
1,845.10 +3.90 (+0.21%)
Biostage, Inc. (BSTG)
Chart Events
Performance Outlook
| Previous Close | 5.34 |
| Open | 4.70 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 5.34 - 5.34 |
| 52 Week Range | 1.11 - 6.80 |
| Volume | |
| Avg. Volume | 2,170 |
| Market Cap | 57.076M |
| Beta (5Y Monthly) | -0.34 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.33 |
| Earnings Date | Nov 15, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Biostage Reports Q1 2022 Financial Results and Corporate Highlights
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating esophageal cancer (conducted at the Mayo Clinic and published last August) and FDA approval to commence a clinical trial of the Biostage Esophageal Implant, or BEI, for severe esophageal disease including cancer, today announced its financial results for the three months ended March 31, 2022, and highlighted recent events.
- PR Newswire
Biostage Announces $5.1 Million Financing to Advance Clinical Trial
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience in treating esophageal cancer (conducted at the Mayo Clinic and published last August) and FDA approval to commence a clinical trial of the Biostage Esophageal Implant for severe esophageal disease including cancer, today announced that it has raised approximately $5.1 million from new and existing investors in a private placement of its shares. Additional de
- PR Newswire
Biostage Schedules Conference Call and Webcast for Q1 2022 Results
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating esophageal cancer (conducted at the Mayo Clinic and published last August) and FDA approval to commence a clinical trial of the Biostage Esophageal Implant for severe esophageal disease including cancer, today announced that it will release Q1 2022 financial results on May. 16th and host a conference call May. 17th to discuss financial results f
